A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8529 When Given as Single and Multiple Ascending Oral Doses in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2009
At a glance
- Drugs AZD 8529 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors AstraZeneca
- 01 Jul 2009 Planned number of patients changed from 36 to 47 as reported by ClinicalTrials.gov.
- 01 Jul 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 20 Oct 2008 New trial record.